ArticleJournal of thoracic disease2018

Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?

Francesco Passiglia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.